Nola Hylton, PhD

Title(s)Professor, Radiology
SchoolSchool of Medicine
Address550 16th Street, #7206
San Francisco CA 94158
Phone--
ORCID ORCID Icon0000-0002-6747-1662 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    Academy of Radiology Research 2013Distinguished Investigator
    Susan G. Komen for the Cure's2010Scientific Advisory Council
    Komen2010Cure Scholar Award
    American College of Radiology Imaging Network2003Outstanding Contribution Award
    American Cancer Society 2003Research Scholar
    Radiology 1987  - 1988Editor's Recognition Award with Distinction
    Stanford University1979Graduate Professional Opportunities Program Fellowship
    Bell Telephone Laboratories 1975Undergraduate Fellowship

    Collapse Overview 
    Collapse Overview
    Nola Hylton, PhD, is a Professor in Residence in the Department of Radiology and Biomedical Imaging, and Director of the Breast Imaging Research Group at the University of California, San Francisco. Dr. Hylton received her BS in Chemical Engineering from the Massachusetts Institute of Technology in Cambridge, Massachusetts in 1979, and she obtained her PhD in Applied Physics from Stanford University, California in 1985.

    Dr. Hylton has been integrally involved in the development of magnetic resonance imaging for the detection, diagnosis, and staging of breast cancer. Dr. Hylton is an internationally known leader in the field of breast MRI for more than 20 years. Her search has addressed the clinical optimization and evaluation of breast MRI technology. Her current research program focuses on the development and clinical evaluation of MRI techniques for characterizing breast cancers and assessing their response to treatment. Her laboratory collaborates closely with a multi-disciplinary team of radiologists, surgeons, oncologists, and science researchers nation wide. This is to optimize MRI techniques for the clinical management of breast cancer patients.

    Dr. Hylton is among the first group of scholars named the Susan G. Komen for the Cure’s Scientific Advisory Council. She served as co-leader for the DHHS office of Women’s Health International Working Group where she identified and addressed barriers to clinical dissemination of breast MRI. She also served as the institutional Principal Investigator of the NCI International Breast MRI Consortium, which is the first large multi-center clinical trial evaluating breast MRI for breast cancer diagnosing and staging.

    Dr. Hylton has over 80 published research articles, and she has written 13 book chapters and over 130 abstracts.

    Expertise:
    Breast Imaging

    Specialty:
    Breast cancer imaging, breast MRI

    Professional Interests:
    Breast cancer, magnetic resonance imaging, medical imaging, breast cancer detection and diagnosis, treatment assessment, optical imaging, molecular imaging, functional imaging, small animal imaging

    Education and Training:
    • Bachelor of Science: Massachusetts Institute of Technology (MIT), Cambridge - Chemical Engineering
    • Doctor of Philosophy: Stanford University, California - Applied Physics

    Collapse Research 
    Collapse Research Activities and Funding
    Quantitative Imaging for Assessing Breast Cancer Response to Treatment
    NIH U01CA151235Sep 26, 2011 - Aug 31, 2016
    Role: Principal Investigator
    Real-time In Vivo MRI Biomarkers for Breast Cancer Pre-Operative Treatment Trials
    NIH R01CA132870Apr 25, 2008 - Jun 30, 2021
    Role: Principal Investigator
    MRI For Staging DCIS and Assessing Response to Treatment
    NIH R01CA116182Aug 23, 2006 - Jul 31, 2013
    Role: Principal Investigator
    Mechanism-Based Evaluations of ErbB-Targeted Agents
    NIH U54CA090788Sep 26, 2001 - Dec 31, 2008
    Role: Co-Investigator
    Anatomic and Biologic Staging of Breast Disease with MRI
    NIH R01CA069587Jan 15, 1997 - Feb 28, 2012
    Role: Principal Investigator
    NMR Imaging and Spectroscopy
    NIH P41RR008079Jun 1, 1993 - May 31, 2013
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Academic Senate

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Cell-free DNA concentration as a biomarker of response and recurrence in HER2-negative breast cancer receiving neoadjuvant chemotherapy. Clin Cancer Res. 2024 Mar 12. Magbanua MJM, Ahmed Z, Sayaman RW, Brown Swigart L, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Perlmutter J, Pohlmann P, Symmans WF, Yee D, Hylton NM, Esserman LJ, DeMichele AM, Rugo HS, van 't Veer LJ. PMID: 38470545.
      View in: PubMed   Mentions:    Fields:    
    2. 18F-FDG Dedicated Breast PET Complementary to Breast MRI for Evaluating Early Response to Neoadjuvant Chemotherapy. Radiol Imaging Cancer. 2024 Mar; 6(2):e230082. Diwanji D, Onishi N, Hathi DK, Lawhn-Heath C, Kornak J, Li W, Guo R, Molina-Vega J, Seo Y, Flavell RR, Heditsian D, Brain S, Esserman LJ, Joe BN, Hylton NM, Jones EF, Ray KM. PMID: 38551406.
      View in: PubMed   Mentions:    Fields:    
    3. Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery. Clin Cancer Res. 2024 Feb 16; 30(4):729-740. Albain KS, Yau C, Petricoin EF, Wolf DM, Lang JE, Chien AJ, Haddad T, Forero-Torres A, Wallace AM, Kaplan H, Pusztai L, Euhus D, Nanda R, Elias AD, Clark AS, Godellas C, Boughey JC, Isaacs C, Tripathy D, Lu J, Yung RL, Gallagher RI, Wulfkuhle JD, Brown-Swigart L, Krings G, Chen YY, Potter DA, Stringer-Reasor E, Blair S, Asare SM, Wilson A, Hirst GL, Singhrao R, Buxton M, Clennell JL, Sanil A, Berry S, Asare AL, Matthews JB, DeMichele AM, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Symmans WF, Van't Veer LJ, Yee D, Berry DA, Esserman LJ. PMID: 38109213.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    4. Breast Multiparametric MRI for Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer: The BMMR2 Challenge. Radiol Imaging Cancer. 2024 Jan; 6(1):e230033. Li W, Partridge SC, Newitt DC, Steingrimsson J, Marques HS, Bolan PJ, Hirano M, Bearce BA, Kalpathy-Cramer J, Boss MA, Teng X, Zhang J, Cai J, Kontos D, Cohen EA, Mankowski WC, Liu M, Ha R, Pellicer-Valero OJ, Maier-Hein K, Rabinovici-Cohen S, Tlusty T, Ozery-Flato M, Parekh VS, Jacobs MA, Yan R, Sung K, Kazerouni AS, DiCarlo JC, Yankeelov TE, Chenevert TL, Hylton NM. PMID: 38180338; PMCID: PMC10825718.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial. Cell Rep Med. 2023 12 19; 4(12):101312. Gallagher RI, Wulfkuhle J, Wolf DM, Brown-Swigart L, Yau C, O'Grady N, Basu A, Lu R, Campbell MJ, Magbanua MJ, Coppé JP, I-SPY 2 Investigators, Asare SM, Sit L, Matthews JB, Perlmutter J, Hylton N, Liu MC, Symmans WF, Rugo HS, Isaacs C, DeMichele AM, Yee D, Pohlmann PR, Hirst GL, Esserman LJ, van 't Veer LJ, Petricoin EF. PMID: 38086377; PMCID: PMC10772394.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. Effect of Longitudinal Variation in Tumor Volume Estimation for MRI-guided Personalization of Breast Cancer Neoadjuvant Treatment. Radiol Imaging Cancer. 2023 07; 5(4):e220126. Onishi N, Bareng TJ, Gibbs J, Li W, Price ER, Joe BN, Kornak J, Esserman LJ, Newitt DC, Hylton NM, I-SPY 2 Imaging Working Group, I-SPY 2 Investigator Network. PMID: 37505107; PMCID: PMC10413289.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    7. Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes. Front Oncol. 2023; 13:1192208. Yu K, Basu A, Yau C, Wolf DM, Goodarzi H, Bandyopadhyay S, Korkola JE, Hirst GL, Asare S, DeMichele A, Hylton N, Yee D, Esserman L, van 't Veer L, Sirota M. PMID: 37384294; PMCID: PMC10294228.
      View in: PubMed   Mentions:
    8. Comparison of Mammography AI Algorithms with a Clinical Risk Model for 5-year Breast Cancer Risk Prediction: An Observational Study. Radiology. 2023 06; 307(5):e222733. Arasu VA, Habel LA, Achacoso NS, Buist DSM, Cord JB, Esserman LJ, Hylton NM, Glymour MM, Kornak J, Kushi LH, Lewis DA, Liu VX, Lydon CM, Miglioretti DL, Navarro DA, Pu A, Shen L, Sieh W, Yoon HC, Lee C. PMID: 37278627; PMCID: PMC10315521.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    9. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. Cancer Cell. 2023 06 12; 41(6):1091-1102.e4. Magbanua MJM, Brown Swigart L, Ahmed Z, Sayaman RW, Renner D, Kalashnikova E, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Asare S, Liu MC, Albain K, Chien AJ, Forero-Torres A, Isaacs C, Nanda R, Tripathy D, Rodriguez A, Sethi H, Aleshin A, Rabinowitz M, Perlmutter J, Symmans WF, Yee D, Hylton NM, Esserman LJ, DeMichele AM, Rugo HS, van 't Veer LJ. PMID: 37146605; PMCID: PMC10330514.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    10. Radiomic tumor phenotypes augment molecular profiling in predicting recurrence free survival after breast neoadjuvant chemotherapy. Commun Med (Lond). 2023 Mar 30; 3(1):46. Chitalia R, Miliotis M, Jahani N, Tastsoglou S, McDonald ES, Belenky V, Cohen EA, Newitt D, Van't Veer LJ, Esserman L, Hylton N, DeMichele A, Hatzigeorgiou A, Kontos D. PMID: 36997615; PMCID: PMC10063641.
      View in: PubMed   Mentions: 2  
    11. Deep Learning to Simulate Contrast-enhanced Breast MRI of Invasive Breast Cancer. Radiology. 2023 Mar; 306(3):e239004. Chung M, Calabrese E, Mongan J, Ray KM, Hayward JH, Kelil T, Sieberg R, Hylton N, Joe BN, Lee AY. PMID: 36803003.
      View in: PubMed   Mentions:    Fields:    
    12. Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer. NPJ Breast Cancer. 2022 Dec 01; 8(1):128. Lang JE, Forero-Torres A, Yee D, Yau C, Wolf D, Park J, Parker BA, Chien AJ, Wallace AM, Murthy R, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Yung RL, Isaacs C, Clark AS, Han HS, Nanda R, Khan QJ, Edmiston KK, Stringer-Reasor E, Price E, Joe B, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Buxton M, Clennell JL, Sanil A, Berry S, Asare SM, Wilson A, Hirst GL, Singhrao R, Asare AL, Matthews JB, Melisko M, Perlmutter J, Rugo HS, Symmans WF, van 't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ. PMID: 36456573; PMCID: PMC9715670.
      View in: PubMed   Mentions: 5  
    13. Deep Learning to Simulate Contrast-enhanced Breast MRI of Invasive Breast Cancer. Radiology. 2023 03; 306(3):e213199. Chung M, Calabrese E, Mongan J, Ray KM, Hayward JH, Kelil T, Sieberg R, Hylton N, Joe BN, Lee AY. PMID: 36378030; PMCID: PMC9974793.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    14. Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy. Cancers (Basel). 2022 Sep 13; 14(18). Li W, Le NN, Onishi N, Newitt DC, Wilmes LJ, Gibbs JE, Carmona-Bozo J, Liang J, Partridge SC, Price ER, Joe BN, Kornak J, Magbanua MJM, Nanda R, LeStage B, Esserman LJ, Van't Veer LJ, Hylton NM. PMID: 36139594; PMCID: PMC9497087.
      View in: PubMed   Mentions: 2  
    15. Expert tumor annotations and radiomics for locally advanced breast cancer in DCE-MRI for ACRIN 6657/I-SPY1. Sci Data. 2022 07 23; 9(1):440. Chitalia R, Pati S, Bhalerao M, Thakur SP, Jahani N, Belenky V, McDonald ES, Gibbs J, Newitt DC, Hylton NM, Kontos D, Bakas S. PMID: 35871247; PMCID: PMC9308769.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    16. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. Cancer Cell. 2022 06 13; 40(6):609-623.e6. Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Lee PRE, Zhu Z, Magbanua MJ, Sayaman R, O'Grady N, Basu A, Delson A, Coppé JP, Lu R, Braun J, I-SPY2 Investigators, Asare SM, Sit L, Matthews JB, Perlmutter J, Hylton N, Liu MC, Pohlmann P, Symmans WF, Rugo HS, Isaacs C, DeMichele AM, Yee D, Berry DA, Pusztai L, Petricoin EF, Hirst GL, Esserman LJ, van 't Veer LJ. PMID: 35623341; PMCID: PMC9426306.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCTClinical Trials
    17. Effect of Inter-Reader Variability on Diffusion-Weighted MRI Apparent Diffusion Coefficient Measurements and Prediction of Pathologic Complete Response for Breast Cancer. Tomography. 2022 04 22; 8(3):1208-1220. Le NN, Li W, Onishi N, Newitt DC, Gibbs JE, Wilmes LJ, Kornak J, Partridge SC, LeStage B, Price ER, Joe BN, Esserman LJ, Hylton NM. PMID: 35645385; PMCID: PMC9149942.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    18. Impact of deformable registration methods for prediction of recurrence free survival response to neoadjuvant chemotherapy in breast cancer: Results from the ISPY 1/ACRIN 6657 trial. Transl Oncol. 2022 Jun; 20:101411. Thakran S, Cohen E, Jahani N, Weinstein SP, Pantalone L, Hylton N, Newitt D, DeMichele A, Davatzikos C, Kontos D. PMID: 35395604; PMCID: PMC8990167.
      View in: PubMed   Mentions: 2  
    19. Post-Processing Bias Field Inhomogeneity Correction for Assessing Background Parenchymal Enhancement on Breast MRI as a Quantitative Marker of Treatment Response. Tomography. 2022 03 22; 8(2):891-904. Nguyen AA, Onishi N, Carmona-Bozo J, Li W, Kornak J, Newitt DC, Hylton NM. PMID: 35448706; PMCID: PMC9027600.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    20. Impact of Alternate b-Value Combinations and Metrics on the Predictive Performance and Repeatability of Diffusion-Weighted MRI in Breast Cancer Treatment: Results from the ECOG-ACRIN A6698 Trial. Tomography. 2022 03 04; 8(2):701-717. Partridge SC, Steingrimsson J, Newitt DC, Gibbs JE, Marques HS, Bolan PJ, Boss MA, Chenevert TL, Rosen MA, Hylton NM. PMID: 35314635; PMCID: PMC8938828.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    21. Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial. Nat Commun. 2021 11 05; 12(1):6428. Clark AS, Yau C, Wolf DM, Petricoin EF, van 't Veer LJ, Yee D, Moulder SL, Wallace AM, Chien AJ, Isaacs C, Boughey JC, Albain KS, Kemmer K, Haley BB, Han HS, Forero-Torres A, Elias A, Lang JE, Ellis ED, Yung R, Tripathy D, Nanda R, Wulfkuhle JD, Brown-Swigart L, Gallagher RI, Helsten T, Roesch E, Ewing CA, Alvarado M, Crane EP, Buxton M, Clennell JL, Paoloni M, Asare SM, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Melisko M, Perlmutter J, Rugo HS, Schwab RB, Symmans WF, Hylton NM, Berry DA, Esserman LJ, DeMichele AM. PMID: 34741023; PMCID: PMC8571284.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    22. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial. JAMA Oncol. 2021 Nov 01; 7(11):1654-1663. Symmans WF, Yau C, Chen YY, Balassanian R, Klein ME, Pusztai L, Nanda R, Parker BA, Datnow B, Krings G, Wei S, Feldman MD, Duan X, Chen B, Sattar H, Khazai L, Zeck JC, Sams S, Mhawech-Fauceglia P, Rendi M, Sahoo S, Ocal IT, Fan F, LeBeau LG, Vinh T, Troxell ML, Chien AJ, Wallace AM, Forero-Torres A, Ellis E, Albain KS, Murthy RK, Boughey JC, Liu MC, Haley BB, Elias AD, Clark AS, Kemmer K, Isaacs C, Lang JE, Han HS, Edmiston K, Viscusi RK, Northfelt DW, Khan QJ, Leyland-Jones B, Venters SJ, Shad S, Matthews JB, Asare SM, Buxton M, Asare AL, Rugo HS, Schwab RB, Helsten T, Hylton NM, van 't Veer L, Perlmutter J, DeMichele AM, Yee D, Berry DA, Esserman LJ. PMID: 34529000; PMCID: PMC8446908.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    23. Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer. NPJ Breast Cancer. 2021 Oct 05; 7(1):131. Yee D, Isaacs C, Wolf DM, Yau C, Haluska P, Giridhar KV, Forero-Torres A, Jo Chien A, Wallace AM, Pusztai L, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Kemmer K, Yung RL, Pohlmann PR, Tripathy D, Clark AS, Han HS, Nanda R, Khan QJ, Edmiston KK, Petricoin EF, Stringer-Reasor E, Falkson CI, Majure M, Mukhtar RA, Helsten TL, Moulder SL, Robinson PA, Wulfkuhle JD, Brown-Swigart L, Buxton M, Clennell JL, Paoloni M, Sanil A, Berry S, Asare SM, Wilson A, Hirst GL, Singhrao R, Asare AL, Matthews JB, Hylton NM, DeMichele A, Melisko M, Perlmutter J, Rugo HS, Fraser Symmans W, Van't Veer LJ, Berry DA, Esserman LJ. PMID: 34611148; PMCID: PMC8492731.
      View in: PubMed   Mentions: 10  
    24. 18F-FDG PET/CT Predicts Response to HER2-directed Neoadjuvant Therapy. Radiol Imaging Cancer. 2021 09; 3(5):e219021. Diwanji D, Ray K, Hylton N. PMID: 34533375; PMCID: PMC8489446.
      View in: PubMed   Mentions:    Fields:    
    25. Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response. Radiology. 2021 11; 301(2):295-308. Onishi N, Li W, Newitt DC, Harnish RJ, Strand F, Nguyen AA, Arasu VA, Gibbs J, Jones EF, Wilmes LJ, Kornak J, Joe BN, Price ER, Ojeda-Fournier H, Eghtedari M, Zamora KW, Woodard S, Umphrey HR, Nelson MT, Church AL, Bolan PJ, Kuritza T, Ward K, Morley K, Wolverton D, Fountain K, Lopez Paniagua D, Hardesty L, Brandt KR, McDonald ES, Rosen M, Kontos D, Abe H, Sheth D, Crane E, Dillis C, Sheth P, Hovanessian-Larsen L, Bang DH, Porter B, Oh KY, Jafarian N, Tudorica LA, Niell B, Drukteinis J, Newell MS, Giurescu ME, Berman E, Lehman CD, Partridge SC, Fitzpatrick KA, Borders MH, Yang WT, Dogan B, Goudreau SH, Chenevert T, Yau C, DeMichele A, Berry DA, Esserman LJ, Hylton NM. PMID: 34427465; PMCID: PMC8574064.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    26. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Cancer Cell. 2021 07 12; 39(7):989-998.e5. Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, Beckwith H, Nanda R, Albain KS, Clark AS, Kemmer K, Kalinsky K, Isaacs C, Thomas A, Shatsky R, Helsten TL, Forero-Torres A, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Asare SM, Wilson A, Singhrao R, Sit L, Hirst GL, Berry S, Sanil A, Asare AL, Matthews JB, Perlmutter J, Melisko M, Rugo HS, Schwab RB, Symmans WF, Yee D, Van't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ. PMID: 34143979.
      View in: PubMed   Mentions: 80     Fields:    Translation:HumansCTClinical Trials
    27. Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection. NPJ Breast Cancer. 2021 May 25; 7(1):59. Glencer AC, Wong JM, Hylton NM, Krings G, McCune E, Rothschild HT, Loveday TA, Alvarado MD, Esserman LJ, Campbell MJ, Campbell MJ. PMID: 34035311; PMCID: PMC8149838.
      View in: PubMed   Mentions: 2  
    28. Mask-Guided Convolutional Neural Network for Breast Tumor Prognostic Outcome Prediction on 3D DCE-MR Images. J Digit Imaging. 2021 06; 34(3):630-636. Liu G, Mitra D, Jones EF, Franc BL, Behr SC, Nguyen A, Bolouri MS, Wisner DJ, Joe BN, Esserman LJ, Hylton NM, Seo Y. PMID: 33885991; PMCID: PMC8329098.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    29. Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk. NPJ Breast Cancer. 2021 Mar 25; 7(1):32. Magbanua MJM, Li W, Wolf DM, Yau C, Hirst GL, Swigart LB, Newitt DC, Gibbs J, Delson AL, Kalashnikova E, Aleshin A, Zimmermann B, Chien AJ, Tripathy D, Esserman L, Hylton N, van 't Veer L. PMID: 33767190; PMCID: PMC7994408.
      View in: PubMed   Mentions: 17  
    30. Accuracy of breast MRI in evaluating nodal status after neoadjuvant therapy in invasive lobular carcinoma. NPJ Breast Cancer. 2021 Mar 05; 7(1):25. Abel MK, Greenwood H, Kelil T, Guo R, Brabham C, Hylton N, Wong J, Alvarado M, Ewing C, Esserman LJ, Boughey JC, Mukhtar RA. PMID: 33674614; PMCID: PMC7935955.
      View in: PubMed   Mentions: 5  
    31. The Way of the Future: Personalizing Treatment Plans Through Technology. Am Soc Clin Oncol Educ Book. 2021 Mar; 41:1-12. Liefaard MC, Lips EH, Wesseling J, Hylton NM, Lou B, Mansi T, Pusztai L. PMID: 33793316.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    32. Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy. Ann Oncol. 2021 05; 32(5):642-651. Du L, Yau C, Brown-Swigart L, Gould R, Krings G, Hirst GL, Bedrosian I, Layman RM, Carter JM, Klein M, Venters S, Shad S, van der Noordaa M, Chien AJ, Haddad T, Isaacs C, Pusztai L, Albain K, Nanda R, Tripathy D, Liu MC, Boughey J, Schwab R, Hylton N, DeMichele A, Perlmutter J, Yee D, Berry D, Van't Veer L, Valero V, Esserman LJ, Symmans WF. PMID: 33617937.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    33. Factors Affecting Image Quality and Lesion Evaluability in Breast Diffusion-weighted MRI: Observations from the ECOG-ACRIN Cancer Research Group Multisite Trial (A6702). J Breast Imaging. 2021 Jan-Feb; 3(1):44-56. Whisenant JG, Romanoff J, Rahbar H, Kitsch AE, Harvey SM, Moy L, DeMartini WB, Dogan BE, Yang WT, Wang LC, Joe BN, Wilmes LJ, Hylton NM, Oh KY, Tudorica LA, Neal CH, Malyarenko DI, McDonald ES, Comstock CE, Yankeelov TE, Chenevert TL, Partridge SC. PMID: 33543122; PMCID: PMC7835633.
      View in: PubMed   Mentions: 3  
    34. Evaluation of primary breast cancers using dedicated breast PET and whole-body PET. Sci Rep. 2020 12 14; 10(1):21930. Hathi DK, Li W, Seo Y, Flavell RR, Kornak J, Franc BL, Joe BN, Esserman LJ, Hylton NM, Jones EF. PMID: 33318514; PMCID: PMC7736887.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    35. Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL. NPJ Breast Cancer. 2020 Nov 27; 6(1):63. Li W, Newitt DC, Gibbs J, Wilmes LJ, Jones EF, Arasu VA, Strand F, Onishi N, Nguyen AA, Kornak J, Joe BN, Price ER, Ojeda-Fournier H, Eghtedari M, Zamora KW, Woodard SA, Umphrey H, Bernreuter W, Nelson M, Church AL, Bolan P, Kuritza T, Ward K, Morley K, Wolverton D, Fountain K, Lopez-Paniagua D, Hardesty L, Brandt K, McDonald ES, Rosen M, Kontos D, Abe H, Sheth D, Crane EP, Dillis C, Sheth P, Hovanessian-Larsen L, Bang DH, Porter B, Oh KY, Jafarian N, Tudorica A, Niell BL, Drukteinis J, Newell MS, Cohen MA, Giurescu M, Berman E, Lehman C, Partridge SC, Fitzpatrick KA, Borders MH, Yang WT, Dogan B, Goudreau S, Chenevert T, Yau C, DeMichele A, Berry D, Esserman LJ, Hylton NM. PMID: 33298938; PMCID: PMC7695723.
      View in: PubMed   Mentions: 16  
    36. Mean Apparent Diffusion Coefficient Is a Sufficient Conventional Diffusion-weighted MRI Metric to Improve Breast MRI Diagnostic Performance: Results from the ECOG-ACRIN Cancer Research Group A6702 Diffusion Imaging Trial. Radiology. 2021 01; 298(1):60-70. McDonald ES, Romanoff J, Rahbar H, Kitsch AE, Harvey SM, Whisenant JG, Yankeelov TE, Moy L, DeMartini WB, Dogan BE, Yang WT, Wang LC, Joe BN, Wilmes LJ, Hylton NM, Oh KY, Tudorica LA, Neal CH, Malyarenko DI, Comstock CE, Schnall MD, Chenevert TL, Partridge SC. PMID: 33201788; PMCID: PMC7771995.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    37. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. JAMA Oncol. 2020 09 01; 6(9):1355-1362. I-SPY2 Trial Consortium, Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, Chen YY, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-Fauceglia P, Magliocco A, Feldman M, Rendi M, Sattar H, Zeck J, Ocal IT, Tawfik O, LeBeau LG, Sahoo S, Vinh T, Chien AJ, Forero-Torres A, Stringer-Reasor E, Wallace AM, Pusztai L, Boughey JC, Ellis ED, Elias AD, Lu J, Lang JE, Han HS, Clark AS, Nanda R, Northfelt DW, Khan QJ, Viscusi RK, Euhus DM, Edmiston KK, Chui SY, Kemmer K, Park JW, Liu MC, Olopade O, Leyland-Jones B, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, Haugen P, Hylton NM, Van't Veer LJ, Perlmutter J, Melisko ME, Wilson A, Peterson G, Asare AL, Buxton MB, Paoloni M, Clennell JL, Hirst GL, Singhrao R, Steeg K, Matthews JB, Asare SM, Sanil A, Berry SM, Esserman LJ, Berry DA. PMID: 32701140; PMCID: PMC7378873.
      View in: PubMed   Mentions: 64     Fields:    Translation:Humans
    38. Predictive Value of Breast MRI Background Parenchymal Enhancement for Neoadjuvant Treatment Response among HER2- Patients. J Breast Imaging. 2020 Aug; 2(4):352-360. Arasu VA, Kim P, Li W, Strand F, McHargue C, Harnish R, Newitt DC, Jones EF, Glymour MM, Kornak J, Esserman LJ, Hylton NM, ISPY2 investigators. PMID: 32803155; PMCID: PMC7418876.
      View in: PubMed   Mentions: 4  
    39. Denoising and Multiple Tissue Compartment Visualization of Multi-b-Valued Breast Diffusion MRI. J Magn Reson Imaging. 2021 01; 53(1):271-282. Tan ET, Wilmes LJ, Joe BN, Onishi N, Arasu VA, Hylton NM, Marinelli L, Newitt DC. PMID: 32614125; PMCID: PMC8406040.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    40. Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy. Cancers (Basel). 2020 Jun 09; 12(6). Jones EF, Hathi DK, Freimanis R, Mukhtar RA, Chien AJ, Esserman LJ, Van't Veer LJ, Joe BN, Hylton NM. PMID: 32527022; PMCID: PMC7352259.
      View in: PubMed   Mentions: 6  
    41. Impact of MRI Protocol Adherence on Prediction of Pathological Complete Response in the I-SPY 2 Neoadjuvant Breast Cancer Trial. Tomography. 2020 06; 6(2):77-85. Onishi N, Li W, Gibbs J, Wilmes LJ, Nguyen A, Jones EF, Arasu V, Kornak J, Joe BN, Esserman LJ, Newitt DC, Hylton NM. PMID: 32548283; PMCID: PMC7289255.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    42. Comparison of Segmentation Methods in Assessing Background Parenchymal Enhancement as a Biomarker for Response to Neoadjuvant Therapy. Tomography. 2020 06; 6(2):101-110. Nguyen AA, Arasu VA, Strand F, Li W, Onishi N, Gibbs J, Jones EF, Joe BN, Esserman LJ, Newitt DC, Hylton NM. PMID: 32548286; PMCID: PMC7289261.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    43. Tumor Sphericity Predicts Response in Neoadjuvant Chemotherapy for Invasive Breast Cancer. Tomography. 2020 06; 6(2):216-222. Li W, Newitt DC, Yun B, Jones EF, Arasu V, Wilmes LJ, Gibbs J, Nguyen AA, Onishi N, Kornak J, Joe BN, Esserman LJ, Hylton NM. PMID: 32548299; PMCID: PMC7289243.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    44. Retrospective Correction of ADC for Gradient Nonlinearity Errors in Multicenter Breast DWI Trials: ACRIN6698 Multiplatform Feasibility Study. Tomography. 2020 06; 6(2):86-92. Malyarenko DI, Newitt DC, Amouzandeh G, Wilmes LJ, Tan ET, Marinelli L, Devaraj A, Peeters JM, Giri S, Vom Endt A, Hylton NM, Partridge SC, Chenevert TL. PMID: 32548284; PMCID: PMC7289257.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    45. Repeatability and Reproducibility of ADC Histogram Metrics from the ACRIN 6698 Breast Cancer Therapy Response Trial. Tomography. 2020 06; 6(2):177-185. Newitt DC, Amouzandeh G, Partridge SC, Marques HS, Herman BA, Ross BD, Hylton NM, Chenevert TL, Malyarenko DI. PMID: 32548294; PMCID: PMC7289237.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    46. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. JAMA Oncol. 2020 05 01; 6(5):676-684. Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, Clark A, Albain K, Boughey JC, Jaskowiak NT, Elias A, Isaacs C, Kemmer K, Helsten T, Majure M, Stringer-Reasor E, Parker C, Lee MC, Haddad T, Cohen RN, Asare S, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Schwab R, Symmans WF, van 't Veer L, Yee D, DeMichele A, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Berry DA, Esserman LJ. PMID: 32053137; PMCID: PMC7058271.
      View in: PubMed   Mentions: 245     Fields:    Translation:HumansCTClinical Trials
    47. Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance). J Clin Oncol. 2020 04 20; 38(12):1284-1292. Hwang ES, Hyslop T, Hendrix LH, Duong S, Bedrosian I, Price E, Caudle A, Hieken T, Guenther J, Hudis CA, Winer E, Lyss AP, Dickson-Witmer D, Hoefer R, Ollila DW, Hardman T, Marks J, Chen YY, Krings G, Esserman L, Hylton N. PMID: 32125937; PMCID: PMC7164489.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    48. Pubertal timing and breast density in young women: a prospective cohort study. Breast Cancer Res. 2019 11 14; 21(1):122. Houghton LC, Jung S, Troisi R, LeBlanc ES, Snetselaar LG, Hylton NM, Klifa C, Van Horn L, Paris K, Shepherd JA, Hoover RN, Dorgan JF. PMID: 31727127; PMCID: PMC6857297.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    49. Complete Breast MRI Response to Neoadjuvant Chemotherapy and Prediction of Pathologic Complete Response. J Breast Imaging. 2019 Sep 04; 1(3):217-222. Chen CA, Hayward JH, Woodard GA, Ray KM, Starr CJ, Hylton NM, Joe BN, Lee AY. PMID: 38424754.
      View in: PubMed   Mentions:
    50. Prediction of Treatment Response to Neoadjuvant Chemotherapy for Breast Cancer via Early Changes in Tumor Heterogeneity Captured by DCE-MRI Registration. Sci Rep. 2019 08 20; 9(1):12114. Jahani N, Cohen E, Hsieh MK, Weinstein SP, Pantalone L, Hylton N, Newitt D, Davatzikos C, Kontos D. PMID: 31431633; PMCID: PMC6702160.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    51. Additive value of diffusion-weighted MRI in the I-SPY 2 TRIAL. J Magn Reson Imaging. 2019 12; 50(6):1742-1753. Li W, Newitt DC, Wilmes LJ, Jones EF, Arasu V, Gibbs J, La Yun B, Li E, Partridge SC, Kornak J, I-SPY 2 Consortium, Esserman LJ, Hylton NM. PMID: 31026118; PMCID: PMC6815231.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    52. Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol. NPJ Breast Cancer. 2019; 5:12. Jones EF, Ray KM, Li W, Chien AJ, Mukhtar RA, Esserman LJ, Franc BL, Seo Y, Pampaloni MH, Joe BN, Hylton NM. PMID: 31016232; PMCID: PMC6467896.
      View in: PubMed   Mentions: 12  
    53. Diffusion-weighted MRI in Multicenter Trials of Breast Cancer. Radiology. 2019 05; 291(2):546. Partridge SC, Newitt DC, Chenevert TL, Rosen MA, Hylton NM, ACRIN 6698 Trial Team and I-SPY 2 Trial Investigators. PMID: 30938630.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    54. MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. J Clin Oncol. 2020 04 01; 38(10):1059-1069. Chien AJ, Tripathy D, Albain KS, Symmans WF, Rugo HS, Melisko ME, Wallace AM, Schwab R, Helsten T, Forero-Torres A, Stringer-Reasor E, Ellis ED, Kaplan HG, Nanda R, Jaskowiak N, Murthy R, Godellas C, Boughey JC, Elias AD, Haley BB, Kemmer K, Isaacs C, Clark AS, Lang JE, Lu J, Korde L, Edmiston KK, Northfelt DW, Viscusi RK, Yee D, Perlmutter J, Hylton NM, Van't Veer LJ, DeMichele A, Wilson A, Peterson G, Buxton MB, Paoloni M, Clennell J, Berry S, Matthews JB, Steeg K, Singhrao R, Hirst GL, Sanil A, Yau C, Asare SM, Berry DA, Esserman LJ, I-SPY 2 Consortium. PMID: 32031889; PMCID: PMC7106976.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCTClinical Trials
    55. Test-retest repeatability and reproducibility of ADC measures by breast DWI: Results from the ACRIN 6698 trial. J Magn Reson Imaging. 2019 06; 49(6):1617-1628. Newitt DC, Zhang Z, Gibbs JE, Partridge SC, Chenevert TL, Rosen MA, Bolan PJ, Marques HS, Aliu S, Li W, Cimino L, Joe BN, Umphrey H, Ojeda-Fournier H, Dogan B, Oh K, Abe H, Drukteinis J, Esserman LJ, Hylton NM, ACRIN Trial Team and I-SPY 2 TRIAL Investigators. PMID: 30350329; PMCID: PMC6524146.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    56. Tissue oxygen saturation predicts response to breast cancer neoadjuvant chemotherapy within 10 days of treatment. J Biomed Opt. 2018 10; 24(2):1-11. Cochran JM, Busch DR, Leproux A, Zhang Z, O'Sullivan TD, Cerussi AE, Carpenter PM, Mehta RS, Roblyer D, Yang W, Paulsen KD, Pogue B, Jiang S, Kaufman PA, Chung SH, Schnall M, Snyder BS, Hylton N, Carp SA, Isakoff SJ, Mankoff D, Tromberg BJ, Yodh AG. PMID: 30338678; PMCID: PMC6194199.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    57. Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial. Radiology. 2018 12; 289(3):618-627. Partridge SC, Zhang Z, Newitt DC, Gibbs JE, Chenevert TL, Rosen MA, Bolan PJ, Marques HS, Romanoff J, Cimino L, Joe BN, Umphrey HR, Ojeda-Fournier H, Dogan B, Oh K, Abe H, Drukteinis JS, Esserman LJ, Hylton NM, ACRIN 6698 Trial Team and I-SPY 2 Trial Investigators. PMID: 30179110; PMCID: PMC6283325.
      View in: PubMed   Mentions: 98     Fields:    Translation:Humans
    58. Residual Disease after Neoadjuvant Therapy for Breast Cancer: Can MRI Help? Radiology. 2018 11; 289(2):335-336. Hylton NM. PMID: 30152746; PMCID: PMC6209065.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    59. Exploration of PET and MRI radiomic features for decoding breast cancer phenotypes and prognosis. NPJ Breast Cancer. 2018; 4:24. Huang SY, Franc BL, Harnish RJ, Liu G, Mitra D, Copeland TP, Arasu VA, Kornak J, Jones EF, Behr SC, Hylton NM, Price ER, Esserman L, Seo Y. PMID: 30131973; PMCID: PMC6095872.
      View in: PubMed   Mentions: 41  
    60. Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL. JCO Precis Oncol. 2018; 2. Wulfkuhle JD, Yau C, Wolf DM, Vis DJ, Gallagher RI, Brown-Swigart L, Hirst G, Voest EE, DeMichele A, Hylton N, Symmans F, Yee D, Esserman L, Berry D, Liu M, Park JW, Wessels LFA, Van't Veer L, Petricoin EF. PMID: 32914002; PMCID: PMC7446527.
      View in: PubMed   Mentions: 26     Fields:    
    61. The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective. Int J Radiat Oncol Biol Phys. 2018 11 15; 102(4):1219-1235. Press RH, Shu HG, Shim H, Mountz JM, Kurland BF, Wahl RL, Jones EF, Hylton NM, Gerstner ER, Nordstrom RJ, Henderson L, Kurdziel KA, Vikram B, Jacobs MA, Holdhoff M, Taylor E, Jaffray DA, Schwartz LH, Mankoff DA, Kinahan PE, Linden HM, Lambin P, Dilling TJ, Rubin DL, Hadjiiski L, Buatti JM. PMID: 29966725; PMCID: PMC6348006.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    62. Intake of dietary carbohydrates in early adulthood and adolescence and breast density among young women. Cancer Causes Control. 2018 07; 29(7):631-642. Jung S, Goloubeva O, Hylton N, Klifa C, LeBlanc E, Shepherd J, Snetselaar L, Van Horn L, Dorgan JF. PMID: 29802491; PMCID: PMC7365352.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    63. MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial. AJR Am J Roentgenol. 2018 Jun; 210(6):1376-1385. Scheel JR, Kim E, Partridge SC, Lehman CD, Rosen MA, Bernreuter WK, Pisano ED, Marques HS, Morris EA, Weatherall PT, Polin SM, Newstead GM, Esserman LJ, Schnall MD, Hylton NM, ACRIN 6657 Trial Team and I-SPY Investigators Network. PMID: 29708782; PMCID: PMC6615034.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCTClinical Trials
    64. Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL. J Med Imaging (Bellingham). 2018 01; 5(1):011014. Olshen A, Wolf D, Jones EF, Newitt D, van ‘t Veer LJ, Yau C, Esserman L, Wulfkuhle JD, Gallagher RI, Singer L, Petricoin EF, Hylton N, Park CC. PMID: 29296631; PMCID: PMC5741993.
      View in: PubMed   Mentions: 3  
    65. Effect of Background Parenchymal Enhancement on Breast MR Imaging Interpretive Performance in Community-based Practices. Radiology. 2018 03; 286(3):822-829. Ray KM, Kerlikowske K, Lobach IV, Hofmann MB, Greenwood HI, Arasu VA, Hylton NM, Joe BN. PMID: 29072981; PMCID: PMC5831266.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansPHPublic Health
    66. Multisite concordance of apparent diffusion coefficient measurements across the NCI Quantitative Imaging Network. J Med Imaging (Bellingham). 2018 Jan; 5(1):011003. Newitt DC, Malyarenko D, Chenevert TL, Quarles CC, Bell L, Fedorov A, Fennessy F, Jacobs MA, Solaiyappan M, Hectors S, Taouli B, Muzi M, Kinahan PE, Schmainda KM, Prah MA, Taber EN, Kroenke C, Huang W, Arlinghaus LR, Yankeelov TE, Cao Y, Aryal M, Yen YF, Kalpathy-Cramer J, Shukla-Dave A, Fung M, Liang J, Boss M, Hylton N. PMID: 29021993; PMCID: PMC5633866.
      View in: PubMed   Mentions: 19  
    67. Accuracy, repeatability, and interplatform reproducibility of T1 quantification methods used for DCE-MRI: Results from a multicenter phantom study. Magn Reson Med. 2018 05; 79(5):2564-2575. Bane O, Hectors SJ, Wagner M, Arlinghaus LL, Aryal MP, Cao Y, Chenevert TL, Fennessy F, Huang W, Hylton NM, Kalpathy-Cramer J, Keenan KE, Malyarenko DI, Mulkern RV, Newitt DC, Russek SE, Stupic KF, Tudorica A, Wilmes LJ, Yankeelov TE, Yen YF, Boss MA, Taouli B. PMID: 28913930; PMCID: PMC5821553.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    68. DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. NPJ Breast Cancer. 2017; 3:31. Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, Olopade O, van 't Veer L. PMID: 28948212; PMCID: PMC5572474.
      View in: PubMed   Mentions: 44  
    69. Performance assessment of diffuse optical spectroscopic imaging instruments in a 2-year multicenter breast cancer trial J Biomed Opt. 2017 12 01; 22(12):121604. O'Sullivan TD, Cerussi A, Durkin A, Hill B, Hylton N, Yodh AG, Carp SA, Boas D, Jiang S, Paulsen KD, Pogue B, Roblyer D, Yang W, Tromberg BJ. PMID: 29389104; PMCID: PMC5995138.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    70. Dedicated Breast Positron Emission Tomography for the Evaluation of Early Response to Neoadjuvant Chemotherapy in Breast Cancer. Clin Breast Cancer. 2017 06; 17(3):e155-e159. Jones EF, Ray KM, Li W, Seo Y, Franc BL, Chien AJ, Esserman LJ, Pampaloni MH, Joe BN, Hylton NM. PMID: 28110902; PMCID: PMC7337237.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    71. MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial. J Magn Reson Imaging. 2017 07; 46(1):290-302. Bolan PJ, Kim E, Herman BA, Newstead GM, Rosen MA, Schnall MD, Pisano ED, Weatherall PT, Morris EA, Lehman CD, Garwood M, Nelson MT, Yee D, Polin SM, Esserman LJ, Gatsonis CA, Metzger GJ, Newitt DC, Partridge SC, Hylton NM, ACRIN Trial team ISPY-1 Investigators. PMID: 27981651; PMCID: PMC5464996.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    72. Diffusion Tensor Imaging for Assessment of Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer. Tomography. 2016 Dec; 2(4):438-447. Wilmes LJ, Li W, Shin HJ, Newitt DC, Proctor E, Harnish R, Hylton NM. PMID: 29527574; PMCID: PMC5844277.
      View in: PubMed   Mentions: 4     Fields:    
    73. Computational Challenges and Collaborative Projects in the NCI Quantitative Imaging Network. Tomography. 2016 Dec; 2(4):242-249. Farahani K, Kalpathy-Cramer J, Chenevert TL, Rubin DL, Sunderland JJ, Nordstrom RJ, Buatti J, Hylton N. PMID: 28798963; PMCID: PMC5548142.
      View in: PubMed   Mentions: 8     Fields:    
    74. Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL. Tomography. 2016 Dec; 2(4):378-387. Li W, Arasu V, Newitt DC, Jones EF, Wilmes L, Gibbs J, Kornak J, Joe BN, Esserman LJ, Hylton NM, ACRIN 6657 Trial Team and I-SPY Investigators Network. PMID: 28066808; PMCID: PMC5214452.
      View in: PubMed   Mentions: 13     Fields:    
    75. Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging. Cancer Res. 2016 10 15; 76(20):5933-5944. Tromberg BJ, Zhang Z, Leproux A, O'Sullivan TD, Cerussi AE, Carpenter PM, Mehta RS, Roblyer D, Yang W, Paulsen KD, Pogue BW, Jiang S, Kaufman PA, Yodh AG, Chung SH, Schnall M, Snyder BS, Hylton N, Boas DA, Carp SA, Isakoff SJ, Mankoff D, ACRIN 6691 investigators. PMID: 27527559; PMCID: PMC5148152.
      View in: PubMed   Mentions: 54     Fields:    Translation:Humans
    76. Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):11-22. Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA, I-SPY 2 Investigators. PMID: 27406346; PMCID: PMC5259558.
      View in: PubMed   Mentions: 143     Fields:    Translation:HumansCTClinical Trials
    77. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):23-34. Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ, I-SPY 2 Investigators. PMID: 27406347; PMCID: PMC5259561.
      View in: PubMed   Mentions: 221     Fields:    Translation:HumansCTClinical Trials
    78. Early Life Body Fatness, Serum Anti-Müllerian Hormone, and Breast Density in Young Adult Women. Cancer Epidemiol Biomarkers Prev. 2016 07; 25(7):1151-7. Bertrand KA, Baer HJ, Orav EJ, Klifa C, Kumar A, Hylton NM, LeBlanc ES, Snetselaar LG, Van Horn L, Dorgan JF. PMID: 27197299; PMCID: PMC4930720.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    79. Variability and bias assessment in breast ADC measurement across multiple systems. J Magn Reson Imaging. 2016 10; 44(4):846-55. Keenan KE, Peskin AP, Wilmes LJ, Aliu SO, Jones EF, Li W, Kornak J, Newitt DC, Hylton NM. PMID: 27008431; PMCID: PMC5098898.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    80. Design of a breast phantom for quantitative MRI. J Magn Reson Imaging. 2016 09; 44(3):610-9. Keenan KE, Wilmes LJ, Aliu SO, Newitt DC, Jones EF, Boss MA, Stupic KF, Russek SE, Hylton NM. PMID: 26949897; PMCID: PMC4983524.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    81. Effect of Imaging Parameter Thresholds on MRI Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes. PLoS One. 2016; 11(2):e0142047. Lo WC, Li W, Jones EF, Newitt DC, Kornak J, Wilmes LJ, Esserman LJ, Hylton NM. PMID: 26886725; PMCID: PMC4757528.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    82. Quantitative Imaging in Cancer Clinical Trials. Clin Cancer Res. 2016 Jan 15; 22(2):284-90. Yankeelov TE, Mankoff DA, Schwartz LH, Lieberman FS, Buatti JM, Mountz JM, Erickson BJ, Fennessy FM, Huang W, Kalpathy-Cramer J, Wahl RL, Linden HM, Kinahan PE, Zhao B, Hylton NM, Gillies RJ, Clarke L, Nordstrom R, Rubin DL. PMID: 26773162; PMCID: PMC4717912.
      View in: PubMed   Mentions: 59     Fields:    Translation:Humans
    83. Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL. Radiology. 2016 Apr; 279(1):44-55. Hylton NM, Gatsonis CA, Rosen MA, Lehman CD, Newitt DC, Partridge SC, Bernreuter WK, Pisano ED, Morris EA, Weatherall PT, Polin SM, Newstead GM, Marques HS, Esserman LJ, Schnall MD, ACRIN 6657 Trial Team and I-SPY 1 TRIAL Investigators. PMID: 26624971; PMCID: PMC4819899.
      View in: PubMed   Mentions: 102     Fields:    Translation:Humans
    84. Body fatness during childhood and adolescence and breast density in young women: a prospective analysis. Breast Cancer Res. 2015 Jul 16; 17:95. Bertrand KA, Baer HJ, Orav EJ, Klifa C, Shepherd JA, Van Horn L, Snetselaar L, Stevens VJ, Hylton NM, Dorgan JF. PMID: 26174168; PMCID: PMC4502611.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    85. How to use magnetic resonance imaging following neoadjuvant chemotherapy in locally advanced breast cancer. World J Clin Cases. 2015 Jul 16; 3(7):607-13. Price ER, Wong J, Mukhtar R, Hylton N, Esserman LJ. PMID: 26244152; PMCID: PMC4517335.
      View in: PubMed   Mentions: 10  
    86. Adolescent endogenous sex hormones and breast density in early adulthood. Breast Cancer Res. 2015 Jun 04; 17:77. Jung S, Egleston BL, Chandler DW, Van Horn L, Hylton NM, Klifa CC, Lasser NL, LeBlanc ES, Paris K, Shepherd JA, Snetselaar LG, Stanczyk FZ, Stevens VJ, Dorgan JF. PMID: 26041651; PMCID: PMC4468804.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    87. Multi-site clinical evaluation of DW-MRI as a treatment response metric for breast cancer patients undergoing neoadjuvant chemotherapy. PLoS One. 2015; 10(3):e0122151. Galbán CJ, Ma B, Malyarenko D, Pickles MD, Heist K, Henry NL, Schott AF, Neal CH, Hylton NM, Rehemtulla A, Johnson TD, Meyer CR, Chenevert TL, Turnbull LW, Ross BD. PMID: 25816249; PMCID: PMC4376686.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCTClinical Trials
    88. Gradient nonlinearity correction to improve apparent diffusion coefficient accuracy and standardization in the american college of radiology imaging network 6698 breast cancer trial. J Magn Reson Imaging. 2015 Oct; 42(4):908-19. Newitt DC, Tan ET, Wilmes LJ, Chenevert TL, Kornak J, Marinelli L, Hylton N. PMID: 25758543; PMCID: PMC4629811.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    89. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clin Cancer Res. 2015 Jul 01; 21(13):2911-5. DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ. PMID: 25712686; PMCID: PMC4490043.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    90. Extra-mammary findings on breast MRI: a pictorial review. Clin Imaging. 2015 Jul-Aug; 39(4):547-52. Karp NL, Price ER, Wisner DJ, Chang CB, Hylton NM, Joe BN. PMID: 25772531.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    91. Lesion morphology on breast MRI affects targeted ultrasound correlation rate. Eur Radiol. 2015 May; 25(5):1279-84. Hollowell L, Price E, Arasu V, Wisner D, Hylton N, Joe B. PMID: 25500714.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    92. Imaging features of HER2 overexpression in breast cancer: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014 Aug; 23(8):1464-83. Elias SG, Adams A, Wisner DJ, Esserman LJ, van't Veer LJ, Mali WP, Gilhuijs KG, Hylton NM. PMID: 24807204.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    93. Errors in Quantitative Image Analysis due to Platform-Dependent Image Scaling. Transl Oncol. 2014 02; 7(1):65-71. Chenevert TL, Malyarenko DI, Newitt D, Li X, Jayatilake M, Tudorica A, Fedorov A, Kikinis R, Liu TT, Muzi M, Oborski MJ, Laymon CM, Li X, Thomas Y, Jayashree KC, Mountz JM, Kinahan PE, Rubin DL, Fennessy F, Huang W, Hylton N, Ross BD. PMID: 24772209; PMCID: PMC3998685.
      View in: PubMed   Mentions: 26  
    94. Real-Time Measurement of Functional Tumor Volume by MRI to Assess Treatment Response in Breast Cancer Neoadjuvant Clinical Trials: Validation of the Aegis SER Software Platform. Transl Oncol. 2014 Feb; 7(1):94-100. Newitt DC, Aliu SO, Witcomb N, Sela G, Kornak J, Esserman L, Hylton NM. PMID: 24772212; PMCID: PMC3998689.
      View in: PubMed   Mentions: 14  
    95. Image registration for quantitative parametric response mapping of cancer treatment response. Transl Oncol. 2014 Feb; 7(1):101-10. Boes JL, Hoff BA, Hylton N, Pickles MD, Turnbull LW, Schott AF, Rehemtulla A, Chamberlain R, Lemasson B, Chenevert TL, Galbán CJ, Meyer CR, Ross BD. PMID: 24772213; PMCID: PMC3998680.
      View in: PubMed   Mentions: 13  
    96. Repeatability of quantitative MRI measurements in normal breast tissue. Transl Oncol. 2014 Feb; 7(1):130-7. Aliu SO, Jones EF, Azziz A, Kornak J, Wilmes LJ, Newitt DC, Suzuki SA, Klifa C, Gibbs J, Proctor EC, Joe BN, Hylton NM. PMID: 24772216; PMCID: PMC3998684.
      View in: PubMed   Mentions: 9  
    97. Optimized breast MRI functional tumor volume as a biomarker of recurrence-free survival following neoadjuvant chemotherapy. J Magn Reson Imaging. 2014 Aug; 40(2):476-82. Jafri NF, Newitt DC, Kornak J, Esserman LJ, Joe BN, Hylton NM. PMID: 24347097; PMCID: PMC4507716.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    98. Agreement of mammographic measures of volumetric breast density to MRI. PLoS One. 2013; 8(12):e81653. Wang J, Azziz A, Fan B, Malkov S, Klifa C, Newitt D, Yitta S, Hylton N, Kerlikowske K, Shepherd JA. PMID: 24324712; PMCID: PMC3852736.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    99. High-resolution diffusion-weighted imaging for the separation of benign from malignant BI-RADS 4/5 lesions found on breast MRI at 3T. J Magn Reson Imaging. 2014 Sep; 40(3):674-81. Wisner DJ, Rogers N, Deshpande VS, Newitt DN, Laub GA, Porter DA, Kornak J, Joe BN, Hylton NM. PMID: 24214467; PMCID: PMC4014534.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    100. Features of occult invasion in biopsy-proven DCIS at breast MRI. Breast J. 2013 Nov-Dec; 19(6):650-8. Wisner DJ, Hwang ES, Chang CB, Tso HH, Joe BN, Lessing JN, Lu Y, Hylton NM. PMID: 24165314; PMCID: PMC4036640.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    101. High resolution in vivo characterization of apparent diffusion coefficient at the tumor-stromal boundary of breast carcinomas: a pilot study to assess treatment response using proximity-dependent diffusion-weighted imaging. J Magn Reson Imaging. 2014 May; 39(5):1308-13. McLaughlin RL, Newitt DC, Wilmes LJ, Jones EF, Wisner DJ, Kornak J, Proctor E, Joe BN, Hylton NM. PMID: 24719242; PMCID: PMC3983569.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    102. Menstrual and reproductive characteristics and breast density in young women. Cancer Causes Control. 2013 Nov; 24(11):1973-83. Dorgan JF, Klifa C, Deshmukh S, Egleston BL, Shepherd JA, Kwiterovich PO, Van Horn L, Snetselaar LG, Stevens VJ, Robson AM, Lasser NL, Hylton NM. PMID: 23933948; PMCID: PMC3960004.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    103. Breast magnetic resonance imaging for monitoring response to therapy. Magn Reson Imaging Clin N Am. 2013 Aug; 21(3):533-46. Ojeda-Fournier H, de Guzman J, Hylton N. PMID: 23928243.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    104. Triple-negative and non-triple-negative invasive breast cancer: association between MR and fluorine 18 fluorodeoxyglucose PET imaging. Radiology. 2013 Nov; 269(2):354-61. Bolouri MS, Elias SG, Wisner DJ, Behr SC, Hawkins RA, Suzuki SA, Banfield KS, Joe BN, Hylton NM. PMID: 23878283; PMCID: PMC3807081.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    105. Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Ann Surg Oncol. 2013 Nov; 20(12):3823-30. Mukhtar RA, Yau C, Rosen M, Tandon VJ, I-SPY 1 TRIAL and ACRIN 6657 Investigators, Hylton N, Esserman LJ. PMID: 23780381; PMCID: PMC3824937.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCTClinical Trials
    106. Recognizing artifacts and optimizing breast MRI at 1.5 and 3 T. AJR Am J Roentgenol. 2013 Jun; 200(6):W673-82. Yitta S, Joe BN, Wisner DJ, Price ER, Hylton NM. PMID: 23701101.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    107. Accuracy and interpretation time of computer-aided detection among novice and experienced breast MRI readers. AJR Am J Roentgenol. 2013 Jun; 200(6):W683-9. Lehman CD, Blume JD, DeMartini WB, Hylton NM, Herman B, Schnall MD. PMID: 23701102; PMCID: PMC4511702.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    108. Intraductal therapy of ductal carcinoma in situ: a presurgery study. Clin Breast Cancer. 2013 Aug; 13(4):280-6. Mahoney ME, Gordon EJ, Rao JY, Jin Y, Hylton N, Love SM. PMID: 23664819; PMCID: PMC4441524.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    109. MRI enhancement in stromal tissue surrounding breast tumors: association with recurrence free survival following neoadjuvant chemotherapy. PLoS One. 2013; 8(5):e61969. Jones EF, Sinha SP, Newitt DC, Klifa C, Kornak J, Park CC, Hylton NM. PMID: 23667451; PMCID: PMC3646993.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    110. High-resolution diffusion-weighted imaging for monitoring breast cancer treatment response. Acad Radiol. 2013 May; 20(5):581-9. Wilmes LJ, McLaughlin RL, Newitt DC, Singer L, Sinha SP, Proctor E, Wisner DJ, Saritas EU, Kornak J, Shankaranarayanan A, Banerjee S, Jones EF, Joe BN, Hylton NM. PMID: 23570936; PMCID: PMC4507576.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    111. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017. Cancer. 2013 May 15; 119(10):1776-83. De Los Santos JF, Cantor A, Amos KD, Forero A, Golshan M, Horton JK, Hudis CA, Hylton NM, McGuire K, Meric-Bernstam F, Meszoely IM, Nanda R, Hwang ES. PMID: 23436342; PMCID: PMC3939707.
      View in: PubMed   Mentions: 74     Fields:    Translation:Humans
    112. MR imaging for the prediction of breast cancer response to neoadjuvant chemotherapy. Radiology. 2013 Jan; 266(1):367. Hylton N. PMID: 23390630.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    113. Height, adiposity and body fat distribution and breast density in young women. Breast Cancer Res. 2012 Jul 13; 14(4):R107. Dorgan JF, Klifa C, Shepherd JA, Egleston BL, Kwiterovich PO, Himes JH, Gabriel K, Horn L, Snetselaar LG, Stevens VJ, Barton BA, Robson AM, Lasser NL, Deshmukh S, Hylton NM. PMID: 22800711; PMCID: PMC3680938.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    114. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL. Radiology. 2012 Jun; 263(3):663-72. Hylton NM, Blume JD, Bernreuter WK, Pisano ED, Rosen MA, Morris EA, Weatherall PT, Lehman CD, Newstead GM, Polin S, Marques HS, Esserman LJ, Schnall MD, ACRIN 6657 Trial Team and I-SPY 1 TRIAL Investigators. PMID: 22623692; PMCID: PMC3359517.
      View in: PubMed   Mentions: 196     Fields:    Translation:Humans
    115. A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. Lancet Oncol. 2012 Jun; 13(6):e240-8. Fumagalli D, Bedard PL, Nahleh Z, Michiels S, Sotiriou C, Loi S, Sparano JA, Ellis M, Hylton N, Zujewski JA, Hudis C, Esserman L, Piccart M, BIG-NABCG collaboration. PMID: 22652232.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    116. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol. 2012 Sep 10; 30(26):3242-9. Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, van 't Veer L, Hylton N. PMID: 22649152; PMCID: PMC3434983.
      View in: PubMed   Mentions: 196     Fields:    Translation:Humans
    117. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2012 Apr; 132(3):1049-62. Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Livasy C, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, Au A, Hylton N, I-SPY 1 TRIAL Investigators. PMID: 22198468; PMCID: PMC3332388.
      View in: PubMed   Mentions: 178     Fields:    Translation:Humans
    118. High-resolution diffusion-weighted magnetic resonance imaging in patients with locally advanced breast cancer. Acad Radiol. 2012 May; 19(5):526-34. Singer L, Wilmes LJ, Saritas EU, Shankaranarayanan A, Proctor E, Wisner DJ, Chang B, Joe BN, Nishimura DG, Hylton NM. PMID: 22197382; PMCID: PMC3319166.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    119. Diffusion-weighted MRI: influence of intravoxel fat signal and breast density on breast tumor conspicuity and apparent diffusion coefficient measurements. Magn Reson Imaging. 2011 Nov; 29(9):1215-21. Partridge SC, Singer L, Sun R, Wilmes LJ, Klifa CS, Lehman CD, Hylton NM. PMID: 21920686; PMCID: PMC3199288.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCells
    120. Outcome of long term active surveillance for estrogen receptor-positive ductal carcinoma in situ. Breast. 2011 Dec; 20(6):529-33. Meyerson AF, Lessing JN, Itakura K, Hylton NM, Wolverton DE, Joe BN, Esserman LJ, Hwang ES. PMID: 21843942; PMCID: PMC4087114.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    121. MRI in breast cancer therapy monitoring. NMR Biomed. 2011 Jul; 24(6):712-20. McLaughlin R, Hylton N. PMID: 21692116; PMCID: PMC4509744.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    122. Quantitative tissue oxygen measurement in multiple organs using 19F MRI in a rat model. Magn Reson Med. 2011 Dec; 66(6):1722-30. Liu S, Shah SJ, Wilmes LJ, Feiner J, Kodibagkar VD, Wendland MF, Mason RP, Hylton N, Hopf HW, Rollins MD. PMID: 21688315; PMCID: PMC3186821.
      View in: PubMed   Mentions: 24     Fields:    Translation:Animals
    123. Quantification of background enhancement in breast magnetic resonance imaging. J Magn Reson Imaging. 2011 May; 33(5):1229-34. Klifa C, Suzuki S, Aliu S, Singer L, Wilmes L, Newitt D, Joe B, Hylton N. PMID: 21509883; PMCID: PMC3081108.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    124. MRI appearance of tumor recurrence in myocutaneous flap reconstruction after mastectomy. AJR Am J Roentgenol. 2011 Apr; 196(4):W471-5. Peng C, Chang CB, Tso HH, Flowers CI, Hylton NM, Joe BN. PMID: 21427313.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    125. Can signal enhancement ratio (SER) reduce the number of recommended biopsies without affecting cancer yield in occult MRI-detected lesions? Acad Radiol. 2011 Jun; 18(6):716-21. Arasu VA, Chen RC, Newitt DN, Chang CB, Tso H, Hylton NM, Joe BN. PMID: 21420333; PMCID: PMC4506794.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    126. Topographic enhancement mapping of the cancer-associated breast stroma using breast MRI. Integr Biol (Camb). 2011 Apr; 3(4):490-6. Nabavizadeh N, Klifa C, Newitt D, Lu Y, Chen YY, Hsu H, Fisher C, Tokayasu T, Olshen AB, Spellman P, Gray JW, Hylton N, Park CC. PMID: 21416100; PMCID: PMC3698966.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    127. The impact of preoperative magnetic resonance imaging on surgical treatment and outcomes for ductal carcinoma in situ. Clin Breast Cancer. 2011 Mar; 11(1):33-8. Itakura K, Lessing J, Sakata T, Heinzerling A, Vriens E, Wisner D, Alvarado M, Esserman L, Ewing C, Hylton N, Hwang ES. PMID: 21421520; PMCID: PMC4508001.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    128. Adolescent diet and subsequent serum hormones, breast density, and bone mineral density in young women: results of the Dietary Intervention Study in Children follow-up study. Cancer Epidemiol Biomarkers Prev. 2010 Jun; 19(6):1545-56. Dorgan JF, Liu L, Klifa C, Hylton N, Shepherd JA, Stanczyk FZ, Snetselaar LG, Van Horn L, Stevens VJ, Robson A, Kwiterovich PO, Lasser NL, Himes JH, Pettee Gabriel K, Kriska A, Ruder EH, Fang CY, Barton BA. PMID: 20501774; PMCID: PMC2883023.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    129. Role of breast MR imaging in neoadjuvant chemotherapy. Magn Reson Imaging Clin N Am. 2010 May; 18(2):249-58, viii-ix. Le-Petross HC, Hylton N. PMID: 20494310.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    130. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat. 2010 Jan; 119(1):137-44. Garwood ER, Kumar AS, Baehner FL, Moore DH, Au A, Hylton N, Flowers CI, Garber J, Lesnikoski BA, Hwang ES, Olopade O, Port ER, Campbell M, Esserman LJ. PMID: 19728082; PMCID: PMC4087110.
      View in: PubMed   Mentions: 96     Fields:    Translation:Humans
    131. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clin Cancer Res. 2009 Sep 01; 15(17):5569-75. Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM. PMID: 19706807; PMCID: PMC3029022.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    132. Can diffuse optical spectroscopic tomography be used to characterize breast lesions and their response to treatment? Radiology. 2009 Aug; 252(2):330-1. Hylton NM. PMID: 19703876.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    133. Magnetic resonance imaging for secondary assessment of breast density in a high-risk cohort. Magn Reson Imaging. 2010 Jan; 28(1):8-15. Klifa C, Carballido-Gamio J, Wilmes L, Laprie A, Shepherd J, Gibbs J, Fan B, Noworolski S, Hylton N. PMID: 19631485; PMCID: PMC4087111.
      View in: PubMed   Mentions: 59     Fields:    Translation:Humans
    134. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009 Jul; 86(1):97-100. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. PMID: 19440188.
      View in: PubMed   Mentions: 265     Fields:    Translation:Humans
    135. MRI methods for evaluating the effects of tyrosine kinase inhibitor administration used to enhance chemotherapy efficiency in a breast tumor xenograft model. J Magn Reson Imaging. 2009 May; 29(5):1071-9. Aliu SO, Wilmes LJ, Moasser MM, Hann BC, Li KL, Wang D, Hylton NM. PMID: 19388114; PMCID: PMC4511711.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    136. Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol. 2009 Jan 10; 27(2):279-88. Kuerer HM, Albarracin CT, Yang WT, Cardiff RD, Brewster AM, Symmans WF, Hylton NM, Middleton LP, Krishnamurthy S, Perkins GH, Babiera G, Edgerton ME, Czerniecki BJ, Arun BK, Hortobagyi GN. PMID: 19064970.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansAnimals
    137. Invasive breast cancer: predicting disease recurrence by using high-spatial-resolution signal enhancement ratio imaging. Radiology. 2008 Jul; 248(1):79-87. Li KL, Partridge SC, Joe BN, Gibbs JE, Lu Y, Esserman LJ, Hylton NM. PMID: 18566170; PMCID: PMC5410941.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    138. Breast stromal enhancement on MRI is associated with response to neoadjuvant chemotherapy. AJR Am J Roentgenol. 2008 Jun; 190(6):1630-6. Hattangadi J, Park C, Rembert J, Klifa C, Hwang J, Gibbs J, Hylton N. PMID: 18492917.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCellsCTClinical Trials
    139. Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference. J Clin Oncol. 2008 Feb 10; 26(5):791-7. Buchholz TA, Lehman CD, Harris JR, Pockaj BA, Khouri N, Hylton NF, Miller MJ, Whelan T, Pierce LJ, Esserman LJ, Newman LA, Smith BL, Bear HD, Mamounas EP. PMID: 18258988.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    140. Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy. J Magn Reson Imaging. 2007 Dec; 26(6):1618-25. Moasser MM, Wilmes LJ, Wong CH, Aliu S, Li KL, Wang D, Hom YK, Hann B, Hylton NM. PMID: 17968965; PMCID: PMC3024590.
      View in: PubMed   Mentions: 14     Fields:    Translation:Animals
    141. Kinetic assessment of breast tumors using high spatial resolution signal enhancement ratio (SER) imaging. Magn Reson Med. 2007 Sep; 58(3):572-81. Li KL, Henry RG, Wilmes LJ, Gibbs J, Zhu X, Lu Y, Hylton NM. PMID: 17685424; PMCID: PMC4508009.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimalsCells
    142. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imaging. 2007 Apr; 25(3):319-27. Wilmes LJ, Pallavicini MG, Fleming LM, Gibbs J, Wang D, Li KL, Partridge SC, Henry RG, Shalinsky DR, Hu-Lowe D, Park JW, McShane TM, Lu Y, Brasch RC, Hylton NM. PMID: 17371720.
      View in: PubMed   Mentions: 58     Fields:    Translation:Animals
    143. Characterization of breast lesions using the 3D FIESTA sequence and contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging. 2007 Jan; 25(1):82-8. Klifa CS, Shimakawa A, Siraj Z, Gibbs JE, Wilmes LJ, Partridge SC, Proctor E, Hylton NM. PMID: 17173311.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    144. Magnetic resonance imaging captures the biology of ductal carcinoma in situ. J Clin Oncol. 2006 Oct 01; 24(28):4603-10. Esserman LJ, Kumar AS, Herrera AF, Leung J, Au A, Chen YY, Moore DH, Chen DF, Hellawell J, Wolverton D, Hwang ES, Hylton NM. PMID: 17008702; PMCID: PMC4087112.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    145. Biologic significance of false-positive magnetic resonance imaging enhancement in the setting of ductal carcinoma in situ. Am J Surg. 2006 Oct; 192(4):520-4. Kumar AS, Chen DF, Au A, Chen YY, Leung J, Garwood ER, Gibbs J, Hylton N, Esserman LJ. PMID: 16978965; PMCID: PMC4087109.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    146. MR imaging for assessment of breast cancer response to neoadjuvant chemotherapy. Magn Reson Imaging Clin N Am. 2006 Aug; 14(3):383-9, vii. Hylton N. PMID: 17098179.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    147. Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol. 2006 Jul 10; 24(20):3293-8. Hylton N. PMID: 16829653.
      View in: PubMed   Mentions: 154     Fields:    Translation:Humans
    148. Diagnostic architectural and dynamic features at breast MR imaging: multicenter study. Radiology. 2006 Jan; 238(1):42-53. Schnall MD, Blume J, Bluemke DA, DeAngelis GA, DeBruhl N, Harms S, Heywang-Köbrunner SH, Hylton N, Kuhl CK, Pisano ED, Causer P, Schnitt SJ, Thickman D, Stelling CB, Weatherall PT, Lehman C, Gatsonis CA. PMID: 16373758.
      View in: PubMed   Mentions: 136     Fields:    Translation:Humans
    149. Added cancer yield of MRI in screening the contralateral breast of women recently diagnosed with breast cancer: results from the International Breast Magnetic Resonance Consortium (IBMC) trial. J Surg Oncol. 2005 Oct 01; 92(1):9-15; discussion 15-6. Lehman CD, Blume JD, Thickman D, Bluemke DA, Pisano E, Kuhl C, Julian TB, Hylton N, Weatherall P, O'loughlin M, Schnitt SJ, Gatsonis C, Schnall MD. PMID: 16180217.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    150. MRI detection of distinct incidental cancer in women with primary breast cancer studied in IBMC 6883. J Surg Oncol. 2005 Oct 01; 92(1):32-8. Schnall MD, Blume J, Bluemke DA, Deangelis GA, Debruhl N, Harms S, Heywang-Köbrunner SH, Hylton N, Kuhl CK, Pisano ED, Causer P, Schnitt SJ, Smazal SF, Stelling CB, Lehman C, Weatherall PT, Gatsonis CA. PMID: 16180227.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCTClinical Trials
    151. Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: assessment by voxel analysis of dynamic contrast-enhanced MRI. J Magn Reson Imaging. 2005 Oct; 22(4):511-9. Li KL, Wilmes LJ, Henry RG, Pallavicini MG, Park JW, Hu-Lowe DD, McShane TM, Shalinsky DR, Fu YJ, Brasch RC, Hylton NM. PMID: 16161072.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimals
    152. Combined diffuse optical spectroscopy and contrast-enhanced magnetic resonance imaging for monitoring breast cancer neoadjuvant chemotherapy: a case study. J Biomed Opt. 2005 Sep-Oct; 10(5):051503. Shah N, Gibbs J, Wolverton D, Cerussi A, Hylton N, Tromberg BJ. PMID: 16292947.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    153. Paget disease of the breast: findings at magnetic resonance imaging and histopathologic correlation. Invest Radiol. 2005 Jun; 40(6):363-7. Frei KA, Bonel HM, Pelte MF, Hylton NM, Kinkel K. PMID: 15905723.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    154. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol. 2005 Jun; 184(6):1774-81. Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Tripathy D, Wolverton DS, Rugo HS, Hwang ES, Ewing CA, Hylton NM. PMID: 15908529.
      View in: PubMed   Mentions: 100     Fields:    Translation:Humans
    155. Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer. 2005 May 01; 103(9):1898-905. Lehman CD, Blume JD, Weatherall P, Thickman D, Hylton N, Warner E, Pisano E, Schnitt SJ, Gatsonis C, Schnall M, DeAngelis GA, Stomper P, Rosen EL, O'Loughlin M, Harms S, Bluemke DA, International Breast MRI Consortium Working Group. PMID: 15800894.
      View in: PubMed   Mentions: 96     Fields:    Translation:HumansPHPublic Health
    156. Magnetic resonance imaging of the breast: opportunities to improve breast cancer management. J Clin Oncol. 2005 Mar 10; 23(8):1678-84. Hylton N. PMID: 15755976.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    157. Four-phase single-capillary stepwise model for kinetics in arterial spin labeling MRI. Magn Reson Med. 2005 Mar; 53(3):511-8. Li KL, Zhu X, Hylton N, Jahng GH, Weiner MW, Schuff N. PMID: 15723393; PMCID: PMC1941668.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    158. Magnetic resonance imaging of the breast prior to biopsy. JAMA. 2004 Dec 08; 292(22):2735-42. Bluemke DA, Gatsonis CA, Chen MH, DeAngelis GA, DeBruhl N, Harms S, Heywang-Köbrunner SH, Hylton N, Kuhl CK, Lehman C, Pisano ED, Causer P, Schnitt SJ, Smazal SF, Stelling CB, Weatherall PT, Schnall MD. PMID: 15585733.
      View in: PubMed   Mentions: 139     Fields:    Translation:HumansCTClinical Trials
    159. Quantification of breast tissue index from MR data using fuzzy clustering. Conf Proc IEEE Eng Med Biol Soc. 2004; 2004:1667-70. Klifa C, Carballido-Gamio J, Wilmes L, Laprie A, Lobo C, Demicco E, Watkins M, Shepherd J, Gibbs J, Hylton N. PMID: 17272023.
      View in: PubMed   Mentions: 63     Fields:    
    160. Evaluation of gadobenate dimeglumine for contrast-enhanced MRI of the breast. AJR Am J Roentgenol. 2003 Sep; 181(3):677-8. Hylton NM. PMID: 12933458.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    161. Magnetic resonance imaging in patients diagnosed with ductal carcinoma-in-situ: value in the diagnosis of residual disease, occult invasion, and multicentricity. Ann Surg Oncol. 2003 May; 10(4):381-8. Hwang ES, Kinkel K, Esserman LJ, Lu Y, Weidner N, Hylton NM. PMID: 12734086.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    162. Magnetic resonance imaging for primary breast cancer management: current role and new applications. Endocr Relat Cancer. 2002 Jun; 9(2):141-53. Esserman L, Wolverton D, Hylton N. PMID: 12121836.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    163. Menstrual cycle variation of apparent diffusion coefficients measured in the normal breast using MRI. J Magn Reson Imaging. 2001 Oct; 14(4):433-8. Partridge SC, McKinnon GC, Henry RG, Hylton NM. PMID: 11599068.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCells
    164. MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. Ann Surg Oncol. 2001 Jul; 8(6):549-59. Esserman L, Kaplan E, Partridge S, Tripathy D, Rugo H, Park J, Hwang S, Kuerer H, Sudilovsky D, Lu Y, Hylton N. PMID: 11456056.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    165. MR imaging of the breast in patients with positive margins after lumpectomy: influence of the time interval between lumpectomy and MR imaging. AJR Am J Roentgenol. 2000 Dec; 175(6):1577-84. Frei KA, Kinkel K, Bonel HM, Lu Y, Esserman LJ, Hylton NM. PMID: 11090379.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    166. Integration of breast imaging into cancer management. Curr Oncol Rep. 2000 Nov; 2(6):572-81. Esserman LJ, Wolverton D, Hylton N. PMID: 11122895.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    167. Suspension of breast-feeding following gadopentetate dimeglumine administration. Radiology. 2000 Aug; 216(2):325-6. Hylton NM. PMID: 10924547.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    168. Dynamic high-spatial-resolution MR imaging of suspicious breast lesions: diagnostic criteria and interobserver variability. AJR Am J Roentgenol. 2000 Jul; 175(1):35-43. Kinkel K, Helbich TH, Esserman LJ, Barclay J, Schwerin EH, Sickles EA, Hylton NM. PMID: 10882243.
      View in: PubMed   Mentions: 54     Fields:    Translation:Humans
    169. Dedicated Breast MRI Systems Working Group report. J Magn Reson Imaging. 1999 Dec; 10(6):1006-9. Hylton N. PMID: 10581519.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    170. Vascularity assessment of breast lesions with gadolinium-enhanced MR imaging. Magn Reson Imaging Clin N Am. 1999 May; 7(2):411-20, x. Hylton NM. PMID: 10382170.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    171. Semi-automated analysis for MRI of breast tumors. Stud Health Technol Inform. 1999; 62:259-60. Partridge SC, Heumann EJ, Hylton NM. PMID: 10538368.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    172. Contrast-Enhanced Magnetic Resonance Imaging to Assess Tumor Histopathology and Angiogenesis in Breast Carcinoma. Breast J. 1999 Jan; 5(1):13-21. Esserman L, Hylton N, George T, Weidner N. PMID: 11348250.
      View in: PubMed   Mentions: 41     Fields:    
    173. Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging. J Clin Oncol. 1999 Jan; 17(1):110-9. Esserman L, Hylton N, Yassa L, Barclay J, Frankel S, Sickles E. PMID: 10458224.
      View in: PubMed   Mentions: 83     Fields:    Translation:Humans
    174. Technical aspects of breast magnetic resonance imaging. Top Magn Reson Imaging. 1998 Feb; 9(1):3-16. Hylton NM, Kinkel K. PMID: 9617899.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    175. Evaluation of the effects of intravascular MR contrast media (gadolinium dendrimer) on 3D time of flight magnetic resonance angiography of the body. J Magn Reson Imaging. 1996 Mar-Apr; 6(2):3O5-1O. Bourne MW, Margerun L, Hylton N, Campion B, Lai JJ, Derugin N, Higgins CB. PMID: 9132094.
      View in: PubMed   Mentions: 6     Fields:    Translation:Animals
    176. Imaging techniques for breast MR imaging. Magn Reson Imaging Clin N Am. 1994 Nov; 2(4):511-25. Hylton NM, Frankel SD. PMID: 7489305.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    177. Impact of section doubling on MR angiography. Radiology. 1992 Dec; 185(3):899-902. Hylton NM, Simovsky I, Li AJ, Hale JD. PMID: 1438782.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    178. MRA: how it's done and what it shows. Diagn Imaging (San Franc). 1990 Jun; 12(6):117, 120-5. Hylton NM, Du LN, Winkler M. PMID: 10149368.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    179. Oblique reformatting of multislice magnetic resonance images for improved visualization of coronary arteries. J Digit Imaging. 1990 Feb; 3(1):34-7. Hylton NM, Chung WS, Botvinick EH, Schiller NB, Sheldon P, Kaufman L. PMID: 2092801.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    180. Characterization of arterial blood flow using magnetic resonance imaging techniques. Monogr Atheroscler. 1990; 15:32-42. Hylton NM. PMID: 2296250.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    181. Echo-planar pediatric imager. Radiology. 1988 Jan; 166(1 Pt 1):157-63. Crooks LE, Arakawa M, Hylton NM, Avram H, Hoenninger JC, Watts JC, Hale JD, Kaufman L. PMID: 3336674.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    182. The value of relaxation times and density measurements in clinical MRI. Invest Radiol. 1987 Feb; 22(2):158-69. Crooks LE, Hylton NM, Ortendahl DA, Posin JP, Kaufman L. PMID: 3557889.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    183. Partial flip angle MR imaging. Radiology. 1987 Feb; 162(2):531-9. Mills TC, Ortendahl DA, Hylton NM, Crooks LE, Carlson JW, Kaufman L. PMID: 3797669.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    184. Optimal visualization of the cerebrospinal fluid on MRI. AJNR Am J Neuroradiol. 1986 May-Jun; 7(3):403-7. Ortendahl DA, Posin JP, Hylton NM, Mills CM. PMID: 3085445; PMCID: PMC8331350.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    185. Information processing in magnetic resonance imaging. Crit Rev Diagn Imaging. 1986; 26(4):325-58. Hylton NM, Ortendahl DA. PMID: 3545683.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    186. Variable magnetic resonance imaging parameters: effect on detection and characterization of lesions. Radiology. 1985 Jun; 155(3):719-25. Posin JP, Ortendahl DA, Hylton NM, Kaufman L, Watts JC, Crooks LE, Mills CM. PMID: 4001375.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    187. Multiple spin-echo magnetic resonance imaging. Radiology. 1985 05; 155(2):437-42. Feinberg DA, Mills CM, Posin JP, Ortendahl DA, Hylton NM, Crooks LE, Watts JC, Kaufman L, Arakawa M, Hoenninger JC, Brant-Zawadzski M. PMID: 3983396.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    188. Analytical tools for magnetic resonance imaging. Radiology. 1984 Nov; 153(2):479-88. Ortendahl DA, Hylton N, Kaufman L, Watts JC, Crooks LE, Mills CM, Stark DD. PMID: 6091173.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    189. Signal to noise in derived NMR images. Magn Reson Med. 1984 Sep; 1(3):316-38. Ortendahl DA, Hylton NM, Kaufman L, Crooks LE. PMID: 6571562.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    190. NMR in experimental cerebral edema: value of T1 and T2 calculations. AJNR Am J Neuroradiol. 1984 Mar-Apr; 5(2):125-9. Brant-Zawadzki M, Bartkowski HM, Ortendahl DA, Pitts LH, Hylton NM, Nishimura MC, Crooks LE. PMID: 6422714; PMCID: PMC8332535.
      View in: PubMed   Mentions: 9     Fields:    Translation:Animals
    With one click, see people who:

    Mentor Faculty

    Run Clinical Trials

    Work in Global Health Equity

    Offer Student Projects

    See more options in the Advanced Search tab

    Nola's Networks
    Concepts (351)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (84)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB04.

    Copyright © The Regents of the University of California.